News Center
A Brilliant Recap | Jiangsu Lekai Concludes with a Resounding Success at COA 2025!
2025-11-16

From November 12 to 16, 2025, the 24th Orthopaedic Academic Conference of the Chinese Medical Association and the 17th COA Academic Congress were grandly held at the Tianjin National Convention and Exhibition Center. Coinciding with the 20th anniversary of COA and the 45th year since the establishment of the Orthopaedics Branch, this conference focused on the theme "Intelligent Orthopaedics · Exploring Future Frontiers," attracting tens of thousands of orthopaedic professionals from across the country to join in this grand event.








At the exhibition, Jiangsu Lekai meticulously designed its booth around two core product lines—bone cement and collagen—alongside featured products such as PRP, amorphous alloys, and room-temperature aerogel coatings. Leveraging exceptional product performance and a commitment to continuous technological innovation, the company attracted numerous clinical experts and industry partners for in-depth exchanges, fostering enthusiastic discussions on potential collaborations.
Bone cement exhibition Zone




Consistent Quality, Consistent Service
Lekai Bone Cement products share the same heritage as Germany's Heraeus, inheriting over half a century of exceptional quality. Today, the brand has become a leader in the domestic bone cement market.
The Lekai Bone Cement product line comprises three series: PALACOS (for joints), OSTEOPAL (for spine), and COPAL (as a drug carrier). Among them, COPAL Space, the drug-loaded bone cement, is gaining increasing recognition from clinicians and partners for its outstanding antibiotic release performance, demonstrating significant efficacy in local anti-infection treatments. It is poised to continue playing a critical role in related fields, bringing benefits to more patients.
With years of deep expertise in the bone cement field, Jiangsu Lekai possesses systematic core technologies and is well-positioned to support and empower the growth of numerous industry partners in the future.
Collagen Exhibition Zone




Medical Collagen Raw Materials
Jiangsu Lekai has now become the largest source supplier of collagen raw materials in China, injecting strong momentum into the industry's development. Its product range covers a comprehensive series of specifications, including paste, powder, sponge, sheet, plug, film, cream, and solution forms.
PRP Exhibition Zone




Easy Operation, Full Control
The "LEQI LOCKIT" Platelet-Rich Plasma (PRP) Preparation Device is exclusively licensed for patent technology in mainland China from the Netherlands' DSM. With its unique patented design, it achieves extreme lightweight portability, weighing only about 700g in total! Despite its compact size, it delivers powerful performance, reaching a maximum speed of over 16,000 RPM. The entire preparation process is shortened to less than 2 minutes, producing PRP with a concentration 5-8 times that of baseline levels.
Amorphous alloy and room temperature aerosol coating exhibition zone




Amorphous alloy and room temperature aerosol coating Process Characteristics
Amorphous Metal is a unique metallic material lacking a crystalline structure, demonstrating significant application potential in fields such as AI robotic transmission components, orthopedic implants, and surgical instruments.
Aerosol Deposition coating technology enables the rapid deposition of ceramic powders or other inorganic materials, ranging from micrometers to nanometers in size, onto various substrates without the need for heating. The process forms dense coating layers while preserving the material's inherent structural characteristics, thereby providing implants with exceptional surface functionality, bio-integration, and stability.
HiPIMS Physical Vapor Deposition (PVD)vacuum coating technology can produce highly dense film layers. By applying high-quality amorphous metal coatings to various medical devices, it significantly enhances their mechanical performance.

At this conference, Jiangsu Lekai proudly presented its core products once again. We firmly believe that R&D innovation serves as the central engine driving the industry forward, while clinical translation remains the ultimate direction for fulfilling our mission of "benefiting human health." Moving forward, Jiangsu Lekai will continue to uphold this original aspiration, maintain its commitment to consistent quality, and implement care through technology. Together with global partners, we will explore new frontiers in medical technology and co-create a more promising future for the cause of human health.
Prev
A Brilliant Recap | Jiangsu Lekai Concludes with a Resounding Success at COA 2025!
2025-11-19
From November 12 to 16, 2025, the 24th Orthopaedic Academic Conference of the Chinese Medical Association and the 17th COA Academic Congress were grandly held at the Tianjin National Convention and Exhibition Center. Focusing on the theme "Intelligent Orthopaedics · Exploring Future Frontiers," the conference attracted tens of thousands of orthopaedic professionals from across the country to participate in this grand event.
Jiangsu Lekai "Collagen" obtained ISO 13485:2016 standard management system certification!
2025-02-13
Jiangsu Lekai Biotechnology Co., LTD. (hereinafter referred to as "Jiangsu Lekai") "collagen raw material" quality management system in accordance with: ISO 13485:2016 standard, obtained the management system certification certificate, certificate No. : C718165.
2024-12-25
Orthopedic colleagues from all over the country gathered in Wuhan to exchange scientific research, exchange techniques, explore and promote the innovation and transformation of the field of orthopedics in China.